Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edyta Paczkowska

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
International Journal of Molecular Sciences|February 12, 2020
Local and Systemic Humoral Response to Autologous Lineage-Negative Cells Intrathecal Administration in ALS PatientsBartłomiej Baumert, Anna Sobuś, Monika Gołąb-Janowska, et al.
Stem Cells International|July 9, 2019
Influence of Lineage-Negative Stem Cell Therapy on Articulatory Functions in ALS PatientsWioletta Pawlukowska, Bartłomiej Baumert, Monika Gołąb-Janowska, et al.
International Journal of Molecular Sciences|October 14, 2022
CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 CourseEwa Pius-Sadowska, Anna Niedźwiedź, Piotr Kulig, et al.
Stem Cells International|December 31, 2020
Humoral Influence of Repeated Lineage-Negative Stem/Progenitor Cell Administration on Articulatory Functions in ALS PatientsAnna Sobuś, Bartłomiej Baumert, Wioletta Pawlukowska, et al.
Cells|August 6, 2020
Repeated Application of Autologous Bone Marrow-Derived Lineage-Negative Stem/Progenitor Cells-Focus on Immunological Pathways in Patients with ALSBartłomiej Baumert, Anna Sobuś, Monika Gołąb-Janowska, et al.
Journal of Clinical Medicine|October 13, 2021
The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple MyelomaKarolina Łuczkowska, Magdalena Rutka, Dorota Rogińska, et al.
Journal of Clinical Medicine|November 27, 2021
Adjuvant Lineage-Negative Cell Therapy as a Potential Silencer of the Complement-Mediated Immune System in ALS PatientsAnna Sobuś, Bartłomiej Baumert, Monika Gołąb-Janowska, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2021
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation ProgramTomasz Sacha, Elżbieta Szczepanek, Paulina Dumnicka, et al.
Leukemia|March 29, 2024
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Elza Lomaia, Christian Fabisch, et al.
Leukemia|December 21, 2023
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinibKaterina Machova Polakova, Ali Albeer, Vaclava Polivkova, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
International Journal of Molecular Sciences|February 12, 2020
Local and Systemic Humoral Response to Autologous Lineage-Negative Cells Intrathecal Administration in ALS PatientsBartłomiej Baumert, Anna Sobuś, Monika Gołąb-Janowska, et al.
Stem Cells International|July 9, 2019
Influence of Lineage-Negative Stem Cell Therapy on Articulatory Functions in ALS PatientsWioletta Pawlukowska, Bartłomiej Baumert, Monika Gołąb-Janowska, et al.
International Journal of Molecular Sciences|October 14, 2022
CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 CourseEwa Pius-Sadowska, Anna Niedźwiedź, Piotr Kulig, et al.
Stem Cells International|December 31, 2020
Humoral Influence of Repeated Lineage-Negative Stem/Progenitor Cell Administration on Articulatory Functions in ALS PatientsAnna Sobuś, Bartłomiej Baumert, Wioletta Pawlukowska, et al.
Cells|August 6, 2020
Repeated Application of Autologous Bone Marrow-Derived Lineage-Negative Stem/Progenitor Cells-Focus on Immunological Pathways in Patients with ALSBartłomiej Baumert, Anna Sobuś, Monika Gołąb-Janowska, et al.
Journal of Clinical Medicine|October 13, 2021
The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple MyelomaKarolina Łuczkowska, Magdalena Rutka, Dorota Rogińska, et al.
Journal of Clinical Medicine|November 27, 2021
Adjuvant Lineage-Negative Cell Therapy as a Potential Silencer of the Complement-Mediated Immune System in ALS PatientsAnna Sobuś, Bartłomiej Baumert, Monika Gołąb-Janowska, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2021
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation ProgramTomasz Sacha, Elżbieta Szczepanek, Paulina Dumnicka, et al.
Leukemia|March 29, 2024
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Elza Lomaia, Christian Fabisch, et al.
Leukemia|December 21, 2023
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinibKaterina Machova Polakova, Ali Albeer, Vaclava Polivkova, et al.
Pageof 8